Decoding the Molecular Logic of GPCR Signaling

SignAlloMod aims to decode GPCR signaling logic at the single-molecule level using a novel method to enhance drug discovery and pharmacological interventions.

Subsidie
€ 1.499.389
2025

Projectdetails

Introduction

G protein-coupled receptors (GPCRs) are key to human physiology and disease, yet their signaling remains enigmatic. What we do know is that GPCRs signal by means of allosteric communication across the cell membrane, acting as logic gates that relay signals from extracellular ligands to various intracellular transducers.

Current Understanding

Nonetheless, the logic underlying GPCR signaling at the molecular level is not yet understood. This is particularly true of three key signaling phenomena:

  1. Ligand efficacy
  2. Biased signaling
  3. Allosteric modulation

Project Overview

In SignAlloMod, we will address this challenge and investigate the logic of transmembrane signaling through GPCRs at the single-molecule level. We will develop smMDSFRET, a ground-breaking method that integrates single-molecule microfluidic diffusional sizing (smMDS) with single-molecule Förster resonance energy transfer (smFRET).

Methodology

By simultaneously measuring binding (smMDS) and conformations (smFRET), this method will make rigorous, quantitative models of GPCR allostery experimentally accessible. This will allow us to separate, for the first time, ligand-specific from transducer-specific effects in GPCR signaling, thereby decoding the molecular logic of GPCR signaling.

Model Receptors

We will use the adenosine A2A receptor as a well-studied model GPCR to establish our approach. We will then study:

  • Ligand efficacy through the β2 adrenergic receptor
  • Biased signaling through the angiotensin II type 1 receptor
  • Allosteric modulation of all three receptors by ions, small molecules, and lipids

Expected Outcomes

The quantitative insights into ligand-specific and transducer-specific effects afforded by SignAlloMod will redefine our understanding of GPCR signaling. SignAlloMod will provide pharmacological ligand profiles with unprecedented detail, opening new horizons for drug discovery and pharmacological intervention guided by physical principles.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.389
Totale projectbegroting€ 1.499.389

Tijdlijn

Startdatum1-5-2025
Einddatum30-4-2030
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • UNIVERSITAET GRAZpenvoerder

Land(en)

Austria

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Molecular mechanisms of GPCR heteromers signaling

This project aims to elucidate the molecular mechanisms of GPCR heteromer assembly and signaling, focusing on the mGlu2-5HT2A complex to advance drug development for schizophrenia.

€ 1.499.494
ERC Consolid...

Unravelling the Physiological Roles of GPCR Voltage Dependence

This project aims to investigate the physiological roles of GPCR voltage dependence in Drosophila using electrophysiology and imaging to understand its impact on neuronal activity and behavior.

€ 1.992.500
ERC Starting...

Engineered control of cellular circuits

Developing light-controlled proteins to study spatiotemporal dynamics of signaling in active neuron subpopulations during learning, aiming to inform therapies for brain disorders.

€ 1.494.669
ERC Advanced...

Protein function regulation through inserts for response to biological, chemical and physical signals

This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.

€ 2.500.000
ERC Starting...

Unravelling Signalling Heterogeneity using DEEP Learning and MECHANIstic Modelling

This project aims to develop innovative computational methods combining deep learning and mechanistic modeling to predict cell signaling responses and address heterogeneity in cancer treatment.

€ 1.499.466

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Universal GPCR Activity Sensor for Next Generation Drug Discovery

This project aims to develop a novel single-assay technology platform for GPCR drug discovery, enhancing detection and classification of drug candidates to improve efficacy and reduce failures.

€ 2.965.384
EIC Pathfinder

Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

€ 2.998.878